JP2017537100A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537100A5
JP2017537100A5 JP2017528520A JP2017528520A JP2017537100A5 JP 2017537100 A5 JP2017537100 A5 JP 2017537100A5 JP 2017528520 A JP2017528520 A JP 2017528520A JP 2017528520 A JP2017528520 A JP 2017528520A JP 2017537100 A5 JP2017537100 A5 JP 2017537100A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
independently selected
oxo
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017528520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537100A (ja
JP6771464B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/062794 external-priority patent/WO2016086200A1/en
Publication of JP2017537100A publication Critical patent/JP2017537100A/ja
Publication of JP2017537100A5 publication Critical patent/JP2017537100A5/ja
Application granted granted Critical
Publication of JP6771464B2 publication Critical patent/JP6771464B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017528520A 2014-11-27 2015-11-25 Cbpおよび/またはep300インヒビターとしての、4,5,6,7−テトラヒドロ−1h−ピラゾロ[4,3−c]ピリジン−3−アミン化合物 Expired - Fee Related JP6771464B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2014092380 2014-11-27
CNPCT/CN2014/092380 2014-11-27
CN2015092965 2015-10-27
CNPCT/CN2015/092965 2015-10-27
PCT/US2015/062794 WO2016086200A1 (en) 2014-11-27 2015-11-25 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors

Publications (3)

Publication Number Publication Date
JP2017537100A JP2017537100A (ja) 2017-12-14
JP2017537100A5 true JP2017537100A5 (enExample) 2019-01-10
JP6771464B2 JP6771464B2 (ja) 2020-10-21

Family

ID=55024234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017528520A Expired - Fee Related JP6771464B2 (ja) 2014-11-27 2015-11-25 Cbpおよび/またはep300インヒビターとしての、4,5,6,7−テトラヒドロ−1h−ピラゾロ[4,3−c]ピリジン−3−アミン化合物

Country Status (5)

Country Link
US (2) US9763922B2 (enExample)
EP (2) EP3632915A1 (enExample)
JP (1) JP6771464B2 (enExample)
CN (1) CN107531690B (enExample)
WO (1) WO2016086200A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40940A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
JP6639497B2 (ja) 2014-11-10 2020-02-05 ジェネンテック, インコーポレイテッド ブロモドメインインヒビターおよびその使用
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
RU2745999C1 (ru) * 2014-12-05 2021-04-05 Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. Ингибитор бромодомена в качестве адъюванта в противоопухолевой иммунотерапии
WO2016123391A1 (en) 2015-01-29 2016-08-04 Genentech, Inc. Therapeutic compounds and uses thereof
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
WO2017205536A2 (en) * 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
MA45146A (fr) 2016-05-24 2021-03-24 Constellation Pharmaceuticals Inc Dérivés de pyrazolopyridine pour le traitement du cancer
JP2019524740A (ja) 2016-07-25 2019-09-05 エピザイム インコーポレイテッド Crebbp関連癌の治療法
GB201617627D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617630D0 (en) * 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3643703A4 (en) 2017-06-21 2020-12-23 Daiichi Sankyo Co., Ltd. EP300 / CREBBP INHIBITOR
WO2019055877A1 (en) * 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
MX2020004838A (es) 2017-11-02 2020-10-16 Aicuris Gmbh & Co Kg Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
CA3095367A1 (en) * 2018-03-29 2019-10-03 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
GB201806320D0 (en) * 2018-04-18 2018-05-30 Cellcentric Ltd Process
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
EP3587418B1 (en) * 2018-06-29 2021-09-01 Forma Therapeutics, Inc. Inhibitors of creb binding protein (cbp)
IL279734B2 (en) * 2018-06-29 2024-11-01 Forma Therapeutics Inc Inhibiting creb binding protein (cbp)
CN109187832B (zh) * 2018-09-30 2021-07-30 华润三九医药股份有限公司 Lc-ms/ms测定去氧肾上腺素浓度的方法及样品的前处理方法
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
CN111320621B (zh) * 2018-12-14 2022-10-04 中国科学院广州生物医药与健康研究院 一种吲嗪类化合物及其制备方法和应用
CN113646002A (zh) * 2019-02-27 2021-11-12 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
HRP20241237T1 (hr) * 2019-02-27 2024-12-06 Constellation Pharmaceuticals, Inc. Derivati n-(piridinil)acetamida kao inhibitori p300/cbp hat i postupci za njihovu upotrebu
CN113784967B (zh) * 2019-03-15 2024-07-26 福马治疗股份有限公司 用于治疗雄激素受体阳性形式的癌症的组合物和方法
TW202102494A (zh) * 2019-03-15 2021-01-16 美商弗瑪治療公司 抑制環amp-反應元件-結合蛋白(creb)
US20220227760A1 (en) * 2019-05-29 2022-07-21 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN110170052B (zh) * 2019-06-21 2020-07-10 复旦大学 Cbp-p300抑制剂在肠道损伤疾病中的应用
TW202120095A (zh) * 2019-08-05 2021-06-01 美商美國禮來大藥廠 7,8-二氫-4H-吡唑并[4,3-c]氮呯-6-酮化合物
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US12486251B2 (en) 2020-04-25 2025-12-02 Pharmablock Sciences (Nanjing) , Inc. CBP/EP300 inhibitor and use thereof
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
CN116507333B (zh) * 2020-08-27 2025-05-09 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
KR20230080441A (ko) * 2020-10-02 2023-06-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 전사 활성화 단백질의 이미다조피페라진 억제제
JP7777131B2 (ja) 2020-10-02 2025-11-27 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム 転写活性化タンパク質のイミダゾピペラジン阻害剤
US20240122941A1 (en) * 2020-12-25 2024-04-18 National Cancer Center Therapy based on synthetic lethality in swi/snf complex-dysfunction cancer
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2022237892A1 (zh) * 2021-05-14 2022-11-17 武汉朗来科技发展有限公司 一种rock抑制剂的酸加成盐及盐的晶型、组合物和药物用途
KR20240117556A (ko) 2021-11-12 2024-08-01 인실리코 메디신 아이피 리미티드 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도
CN117843618A (zh) * 2022-08-29 2024-04-09 北京沐华生物科技有限责任公司 一种ep300/cbp调节剂及其制备方法和用途
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN121773104A (zh) * 2023-06-30 2026-03-31 北京双鹤润创科技有限公司 肌成束蛋白抑制剂
CN117069956B (zh) * 2023-08-22 2025-04-08 南京科技职业学院 一种具有一维超分子结构的手性膦镍(ii)配合物及其制备方法和应用
AU2024387082A1 (en) 2023-11-21 2026-06-04 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides
CN122270448A (zh) * 2023-11-24 2026-06-23 北京沐华生物科技有限责任公司 一种ep300/cbp调节剂及其制备方法和用途
WO2025222158A1 (en) * 2024-04-19 2025-10-23 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2026090300A1 (en) * 2024-10-23 2026-04-30 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2026128761A1 (en) 2024-12-11 2026-06-18 Nexo Therapeutics, Inc. Covalent p300 inhibitor compounds

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
KR100441557B1 (ko) 1994-07-21 2005-08-05 아크조 노벨 엔.브이. 고리형케톤과산화물조성물
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
PL188959B1 (pl) 1995-07-06 2005-05-31 Novartis Ag Pirolopirymidyny i sposoby ich wytwarzania
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU7165698A (en) 1997-05-06 1998-11-27 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU1308799A (en) 1997-11-06 1999-05-31 American Cyanamid Company Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
CN1160338C (zh) 1998-11-19 2004-08-04 沃尼尔·朗伯公司 N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂
MXPA05000945A (es) 2002-07-25 2005-05-16 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de la cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
US20060100233A1 (en) 2002-07-25 2006-05-11 Manuela Villa Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
BRPI0408486A (pt) 2003-03-11 2006-04-04 Pharmacia Italia Spa derivados de biciclopirazol ativos como inibidores da cinase, processo para a sua preparação e composições farmacêuticas compreendendo-os
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1968976A1 (en) 2005-12-12 2008-09-17 NERVIANO MEDICAL SCIENCES S.r.l. Substituted pyrazolo [4,3-c] pyridine derivatives active as kinase inhibitors
WO2007099166A1 (en) 2006-03-03 2007-09-07 Nerviano Medical Sciences S.R.L. Pyrazolo-pyridine derivatives active as kinase inhibitors
CN101910182B (zh) 2007-12-28 2013-07-17 田边三菱制药株式会社 抗癌剂
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
AR071780A1 (es) 2008-05-15 2010-07-14 Nerviano Medical Sciences Srl Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CN101812063B (zh) 2010-03-18 2012-04-25 中国医学科学院医药生物技术研究所 α-萘磺酰胺基五元杂环类化合物及其抑瘤活性
WO2013097052A1 (en) * 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2013148114A1 (en) * 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use
WO2014138727A1 (en) * 2013-03-08 2014-09-12 Board Of Regents, The University Of Texas System Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein c receptors (epcr)

Similar Documents

Publication Publication Date Title
JP2017530176A5 (enExample)
JP2019516757A5 (enExample)
JP2017526696A5 (enExample)
JP2019516759A5 (enExample)
JP2017533250A5 (enExample)
JP2017525740A5 (enExample)
JP2017533249A5 (enExample)
JP6835472B2 (ja) 癌の処置のための組成物
AU2017200269B2 (en) Methods of using c-Met modulators
JP2018501287A5 (enExample)
CN102985403B (zh) 具有抗雄激素性质的新型芳基酰胺衍生物
RU2020131507A (ru) Имидазопиперазиновые ингибиторы белков-активаторов транскрипции
Li et al. Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain
ZA200307665B (en) Combination comprising N-{5-[4-(4-methyl-piperazinomethyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and a chemotherapeutic agent.
JP2018507191A5 (enExample)
JP2019529444A5 (enExample)
KR20140025433A (ko) Akt 억제제 화합물 및 베무라페닙의 조합물, 및 사용 방법
JP2014506601A5 (enExample)
US20220160672A1 (en) Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof
IL191803A (en) Substances that bind intracranial receptors
CN109843872A (zh) 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
TW201016671A (en) Novel imidazolidine compounds as androgen receptor modulators
JP2011521938A5 (enExample)
CA2604907A1 (en) Combination cancer therapy with bis(thiohydrazide) amide compounds
JP2012514019A (ja) トルイジンスルホンアミド、及び阻害剤としてのそれらの使用